A reflection of Nashville’s entrepreneurial and creative spirit, Sarah Cannon Research Institute becomes one of the first companies to make cancer clinical trials accessible to the public, without the support of an academic institution —an untapped concept at the time. The company is a joint venture between HCA and Tennessee Oncology.
Today, Sarah Cannon Research Institute is HCA’s global cancer arm, with accredited centers across the U.S. and U.K., led by CEO Dee Anna Smith.
